caa a22 4500 605536880 CHVBK 20210128100854.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s10517-015-3104-5 doi (NATIONALLICENCE)springer-10.1007/s10517-015-3104-5 Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2 [Elektronische Daten] [D. Khochenkov, E. Solomko, N. Peretolchina, O. Ryabaya, E. Stepanova] Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis. Springer Science+Business Media New York, 2015 alofanib nationallicence allosteric inhibitor of FGFR2 nationallicence tumor angiogenesis nationallicence endothelial cells nationallicence Khochenkov D. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut Solomko E. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut Peretolchina N. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut Ryabaya O. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut Stepanova E. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 160/1(2015-11-01), 84-87 0007-4888 160:1<84 2015 160 10517 https://doi.org/10.1007/s10517-015-3104-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10517-015-3104-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Khochenkov D. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut NATIONALLICENCE 700 1- Solomko E. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut NATIONALLICENCE 700 1- Peretolchina N. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut NATIONALLICENCE 700 1- Ryabaya O. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut NATIONALLICENCE 700 1- Stepanova E. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia aut NATIONALLICENCE 773 0- Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 160/1(2015-11-01), 84-87 0007-4888 160:1<84 2015 160 10517